Amelioration of Muscular Dystrophy by Transgenic Expression of Niemann-Pick C1

Michelle S. Steen, Marvin E. Adams, Yan Tesch, and Stanley C. Froehner

Department of Physiology and Biophysics, University of Washington, Seattle, WA 98195

Submitted August 7, 2008; Revised October 6, 2008; Accepted October 10, 2008

Monitoring Editor: Robert G. Parton

Duchenne muscular dystrophy (DMD) and other types of muscular dystrophies are caused by the loss or alteration of different members of the dystrophin protein complex. Understanding the molecular mechanisms by which dystrophin-associated protein abnormalities contribute to the onset of muscular dystrophy may identify new therapeutic approaches to these human disorders. By examining gene expression alterations in mouse skeletal muscle lacking α -dystrobrevin (*Dtna*^{−/−}), we identified a highly significant reduction of the cholesterol trafficking protein, Niemann-Pick C1 (NPC1). Mutations in NPC1 cause a progressive neurodegenerative, lysosomal storage disorder. Transgenic expression of NPC1 in skeletal muscle ameliorates muscular dystrophy in the *Dtna*^{−/−} mouse (which has a relatively mild dystrophic phenotype) and in the *mdx* mouse, a model for DMD. These results identify a new compensatory gene for muscular dystrophy and reveal a potential new therapeutic target for DMD.

INTRODUCTION

Duchenne muscular dystrophy (DMD) is a fatal, muscle-wasting disease, affecting ~1 in 3500 live male births. Patients with DMD display muscle weakness early in life, experience progressive loss of mobility due to severe muscle degeneration, and ultimately die in the early twenties, usually from respiratory or cardiac failure. DMD results from the loss of functional dystrophin, a large intracellular membrane protein required for the formation of the dystrophin-associated protein complex (DPC), a large complex of transmembrane glycoproteins (Ervasti *et al.*, 1990), adaptor proteins, and signaling proteins (Hoffman *et al.*, 1987). Despite significant advances in gene therapy aimed at replacing the defective dystrophin gene (Cox *et al.*, 1993; Ragot *et al.*, 1993; Wang *et al.*, 2000; Gregorevic *et al.*, 2006), DMD still remains without an effective treatment.

The DPC forms a physical link between the intracellular actin cytoskeleton and the extracellular matrix. Members of the DPC include the dystroglycans (which provide transmembrane linkage between dystrophin and laminin), γ -actin, the sarcoglycans, and the syntrophin–dystrobrevin scaffold for signaling proteins (Ervasti, 2007). Mutations in DPC proteins cause other forms of muscular dystrophies, such as the limb-girdle muscular dystrophies (Ozawa *et al.*, 2005). Although the DPC complex has been extensively studied, the downstream molecular and cellular alterations that lead to muscle degeneration in DMD are largely unknown. A more complete understanding of these pathways may reveal new therapeutic targets that slow the progression of muscle degeneration.

In this study, we performed gene expression analyses on skeletal muscle from mice lacking α -dystrobrevin (*Dtna*^{−/−}), which display a mild dystrophic phenotype compared with *mdx* mice (Grady *et al.*, 1999), in order to identify new genes contributing to muscular dystrophy. The *Dtna*^{−/−} mice have a highly significant reduction in Niemann-Pick C1 (*Npc1*) transcript and protein. Mutations in *Npc1* are responsible for Niemann-Pick C1 (NPC1) disease, a progressive and ultimately fatal, autosomal recessive, neurodegenerative disease, affecting ~1 in 150,000 live births. The function of NPC1 is not well understood but seems to be involved in regulating intracellular cholesterol transport (Liscum *et al.*, 1989). Cells lacking NPC1 exhibit an accumulation of LDL-derived unesterified cholesterol in the endosomal/lysosomal pathway, which may impair trafficking or other cellular functions (Sokol *et al.*, 1988). NPC1 has been studied extensively in brain and liver, the tissues more severely affected by the disease. The role of NPC1 in skeletal muscle has not been examined, to our knowledge.

To determine whether the restoration of NPC1 improves the health of dystrophic muscle, we expressed *Npc1* in skeletal muscle of both *Dtna*^{−/−} and *mdx* mice. Here, we show that NPC1 expression in skeletal muscle significantly ameliorates the dystrophic phenotype in both of these mouse models of muscular dystrophy. These findings identify NPC1 as a booster gene for compromised muscle (Engvall and Wewer, 2003) and reveal a potential new therapeutic target for muscular dystrophies.

MATERIALS AND METHODS

Animals

Mice lacking dystrophin (*mdx*) and mice heterozygous for the Niemann Pick type C1 mutant allele were obtained from The Jackson Laboratory (Bar Harbor, ME). The NPC1 mutant allele contains the insertion of a retroposon, resulting in a premature truncation, deleting 11 of the 13 transmembrane domains. Breeding pairs were bred to produce *Npc1*-null (*Npc1*^{−/−}), heterozygous (*Npc1*^{+/-}), and wild-type (*Npc1*^{+/+}) offspring. Genotyping was performed according to The Jackson Laboratory protocols (jaxmice.jax.org). *Dtna*^{−/−} mice were a generous gift of Joshua Sanes (Harvard University, Boston, MA). All animal experiments were performed with the approval of

This article was published online ahead of print in *MBC in Press* (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08-08-0811>) on October 22, 2008.

Address correspondence to: Stanley C. Froehner (froehner@u.washington.edu).

Abbreviations used: DMD, Duchenne muscular dystrophy; DPC, dystrophin-associated protein complex; TA, tibialis anterior.

the Institutional Animal Care and Use Committee at the University of Washington (Seattle, WA).

Affymetrix GeneChip Assays

Quadriceps muscles were dissected from 6-wk-old male *Dtna*^{-/-} and their wild-type, sex-matched littermates. Total RNA was isolated from each quadriceps muscle by using TRIzol Reagent (Invitrogen, Carlsbad, CA) and the RNeasy Mini kit (QIAGEN, Valencia, CA). For each sample, 20 µg of total RNA was processed for gene expression analysis, using Affymetrix Murine Genome U74Av2, U74Bv2, and U74Cv2 arrays, following Affymetrix protocols (Affymetrix, Santa Clara, CA; www.affymetrix.com). RNA from eight experimental and eight control mice was analyzed individually on the U74v2 arrays. Double-stranded cDNA was synthesized from total RNA (SuperScript Choice system; Invitrogen). Single-stranded, biotin-labeled cRNA (BioArray HighYield RNA Transcript Labeling kit [T7]; Enzo Diagnostics, New York, NY) was synthesized by *in vitro* transcription, and fragmented. The resulting fragmented, biotin-labeled cRNA (15 µg) was hybridized to the Affymetrix arrays, which were labeled with the GeneChip Fluidics Station 400 (Affymetrix) and scanned with the GeneChip Scanner 3000 (Affymetrix) at the Center for Array Technologies at the University of Washington. Initial data analysis was performed with Affymetrix Microarray Suite 5.0.

Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Real-Time quantitative RT-PCR was performed using TaqMan chemistry and the ABI 7000 sequence detection system (Applied Biosystems, Foster City, CA). Quadriceps muscles were dissected from 6-wk-old male *Dtna*^{-/-} mice and their wild-type, sex-matched littermates. Real-time quantitative RT-PCR was performed on each sample using 50 ng of RNA, One-Step RT-PCR Master Mix reagents (Applied Biosystems), and *Npc1* primers (5'-AATGCGGTCTC-CTTGGTCAA-3' and 5'-GCTCTCGTTATATGGCTGCAGAA-3'; Integrated DNA Technologies, Coralville, IA) and probe (5' 6-FAM d(CACAGAAATGCCACAGCTCATCACCAA) BHQ-1 3', Biosearch Technologies), or control 18S primers and probe (4310893E; Applied Biosystems). The relative expression of *Npc1* mRNA was normalized to 18S RNA in the same sample. Each sample was run in duplicate.

Generation of NPC1 Antibody

A 16-amino acid peptide (KAKRHHTYERYRGTTER), corresponding to the cytosolic carboxy-terminal domain of murine NPC1 (GenBank accession no. BC052437, residues 1256–1271) was synthesized (Macromolecular Resources, Colorado State University, Fort Collins, CO), conjugated to keyhole limpet hemocyanin (Pierce Chemical, Rockford, IL), and injected into New Zealand White rabbits (Covance Research Products, Princeton, NJ). Antibodies were affinity purified using peptide bound to UltraLink Iodoacetyl Gel columns (Pierce Chemical).

Membrane Enrichment and Immunoblots

Tissues were dissected and quick frozen in liquid nitrogen. Membrane preparations and immunoblotting were performed as described previously (Garver *et al.*, 2000) with the following modifications. Tissues were homogenized in buffer A [25 mM 2-(*N*-morpholino)ethanesulfonic acid, pH 6.5, 150 mM NaCl, and protease inhibitors [Sigma-Aldrich, St. Louis]] and centrifuged for 30 min at 100,000 × *g*, generating a cytosolic fraction (supernatant) and membrane-enriched fraction (pellet). Pellets were resuspended in buffer A plus 1% Triton X-100 and centrifuged at 2000 × *g* for 10 min. Protein content was determined using the bicinchoninic acid protein assay (Pierce Chemical). Gels (4–15% or 4–20% Tris-HCl gradient; Bio-Rad, Hercules, CA) were loaded with 5–25 µg of protein and run and transferred to nitrocellulose membrane (Millipore, Billerica, MA). Primary antibody was detected using horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) and SuperSignal West Femto Maximum Sensitivity Substrate (Pierce Chemical) using a charge-coupled device camera (Alpha Innotech, San Leandro, CA).

Immunofluorescence Microscopy

Single muscle fiber preparations were adapted from Percival *et al.* (2007). The fibers were incubated for 45 min in Alexa Fluor 488-conjugated donkey anti-rabbit secondary antibody (Invitrogen) diluted in blocking buffer (0.05% saponin and 10% goat serum in phosphate-buffered saline) and washed. Labeled fibers were separated on glass slides in ProLong Gold antifade mounting media, containing 4,6-diamidino-2-phenylindole (DAPI) (Invitrogen) for visualization of nuclei. Confocal microscopy images were obtained using an LSM 510 META (Carl Zeiss, Thornwood, NY) at the W. M. Keck Center for Advanced Studies in Neural Signaling (University of Washington). Stacks of 40 serial optical sections measuring 0.44 µm in thickness were obtained at 0.44-µm intervals through the muscle fibers, using a Plan-Neofluar 40×/1.3 oil objective at 2× zoom. The sections were merged into a single image using the “maximum” projection method.

Filipin Staining

Teased muscle fibers were incubated with block solution (0.2% bovine serum albumin, 0.2% fish skin gelatin [Sigma-Aldrich] in phosphate-buffered saline) for 20 min. The fibers were stained with block solution containing 1 mg/ml filipin (Sigma-Aldrich) according to the method of Carozzi *et al.* (2000). Fibers were imaged using an Axioskop 2 microscope (Carl Zeiss).

Generation of Transgenic Mice

The cDNA encoding full-length *Npc1* was obtained from American Type Culture Collection (9890203; Manassas, VA). On sequence comparison of this clone (GenBank accession no. BC052437) with that of mouse *Npc1* sequence (GenBank accession no. AF003348), multiple expressed sequence tags, and the mouse genome, we observed several sequence discrepancies. We considered the consensus sequence generated from all of the sequences to be correct. Therefore, by PCR, we made a single base mutation, a3963g, resulting in an amino acid alteration, K1273E, to match the ATCC sequence to that of the consensus. The *Npc1* cDNA was cloned into the NotI site of pBSX-HSAvpA (Crawford *et al.*, 2000), a generous gift from Dr. Jeffrey Chamberlain (University of Washington). The linearized construct was injected into the pronuclei of C57BL/6 × C3H embryos (Transgenic Resources Program, Department of Comparative Medicine, University of Washington), and the resulting progeny were genotyped by PCR (5'-GATGAA GCAGACAGTATTCAGC-3' and 5'-CAGTTCGGCTCGCGGAGCAC-3'). Four founder lines carrying the *Npc1* transgene were identified [Tg(*Npc1*)] and bred onto *Dtna*^{-/-} [*Dtna*^{-/-}-Tg(*Npc1*)] and *mdx* [*mdx*-Tg(*Npc1*)] backgrounds.

Central Nuclei Counts and Fiber Diameter Measurements

Tibialis anterior (TA), soleus, and diaphragm muscles were dissected, embedded in O.C.T. (Tissue-Tek) and quick-frozen in liquid nitrogen-cooled isopentane. Cross sections (8 µm) taken from the midbelly of the muscles were fixed in 95% ethanol and stained with Gill's no. 3 hematoxylin and eosin Y (H&E). Microscope (Axioskop 2; Carl Zeiss) images of the entire muscle were used to assess the presence of centrally located nuclei. A minimum of five mice per genotype was analyzed. *Dtna*^{-/-}-Tg(*Npc1*) were examined at 3 mo of age and *mdx*-Tg(*Npc1*) at 8 wk of age. ImageJ software (National Institutes of Health, Bethesda, MD) was used to measure Feret's diameter (Briguet *et al.*, 2004) of muscle fibers. Measurements were taken from an entire cross section of soleus muscle from each of three mice per genotype examined. Coefficients of variation (percentages) of the fiber diameters were calculated as SD of the muscle fiber size/mean fiber size × 100.

Creatine Kinase Assay

Blood (50–100 µl) was collected from the saphenous vein and allowed to clot for 20 min. Serum was obtained after centrifugation of the blood at 5000 × *g* for 8 min at room temperature. We used the CK Liquid-UV test (StanBio Life Sciences, Elkhart, IN) and followed the manufacturer's protocol for the determination of serum creatine kinase activity. A minimum of five mice per genotype was analyzed.

Statistical Analyses

For statistical analyses of microarray data, two-tailed Student's paired *t* tests were performed on the signal intensities of all probe sets to identify significant differences between the control and experimental groups. A value of *p* < 0.005 was considered significant. A two-tailed Student's paired *t* test was performed on the quantitative RT-PCR data to determine the significance of the difference in *Npc1* expression between the control and experimental groups. We performed one-way analysis of variance tests with Tukey's post test for determination of statistical significance of both central nucleation and creatine kinase activity, using GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA).

RESULTS

Gene Expression Array Analysis of *Dtna*^{-/-} Muscle

To identify genes with altered expression in a mouse model of muscular dystrophy, we compared gene expression levels from muscle of *Dtna*^{-/-} mice to littermate controls. The *Dtna*^{-/-} mouse was chosen for these studies because its mild dystrophy does not evoke the aggressive immune response that predominates gene expression analysis studies in *mdx* muscle (Porter *et al.*, 2002). The goal of these studies was to identify genes with expression altered before the onset of muscle degeneration. To improve the probability of identifying early gene expression changes, we used relatively young mice (6 wk) and selected a muscle (quadriceps) that is only mildly affected (based on histological analysis).

Figure 1. Reduction of *Npc1* mRNA and NPC1 protein in *Dtna*^{-/-} quadriceps muscle. (A) Real-time RT-PCR was used to determine *Npc1* transcript levels (arbitrary units) in wild-type and *Dtna*^{-/-} quadriceps muscle. Data are shown as mean $\pm$ SD; * $p < 0.05$ versus wild type. (B) Immunoblot analysis of NPC1 levels in membrane-enriched fractions prepared from wild-type and *Dtna*^{-/-} mouse quadriceps muscles. Two examples are shown.

We analyzed large numbers of muscle samples independently so that even small, but statistically significant changes would be revealed. Using this approach, we identified >200 transcripts that were differentially regulated in *Dtna*^{-/-} muscle (Supplemental Tables 1 and 2). Because of its high level of statistical significance ($p = 3.0 \times 10^{-7}$) and its involvement in a known neurodegenerative disease, our attention was directed toward the gene encoding *Npc1*. The array data indicated that the expression level of *Npc1* transcript is reduced by ~50% in the *Dtna*^{-/-} muscle (Supplemental Table 1). We used real-time quantitative RT-PCR to confirm the 50% reduction ($p < 0.05$) of *Npc1* transcript in *Dtna*^{-/-} quadriceps muscle (Figure 1).

Because reduction in mRNA does not necessarily lead to a reduction in protein levels we compared NPC1 protein levels in wild-type and *Dtna*^{-/-} muscle (Figure 1). Like the *Npc1* transcript levels, NPC1 protein levels are also markedly decreased in *Dtna*^{-/-} muscle, compared with wild-type samples. This was particularly evident in the membrane-enriched samples as expected for the transmembrane NPC1 (Figure 1).

We used immunofluorescence to determine the location of NPC1 in skeletal muscle (Figure 2). Labeling of individual

muscle fibers using our NPC1 antibody showed a specific punctate pattern not present in the NPC1 knockout muscle. This labeling colocalized with lysosomal membrane protein (LAMP1), a lysosomal marker (Figure 2).

Production of Transgenic NPC1 Mice

Having established that the levels of NPC1 were reduced in the *Dtna*^{-/-} mouse model of muscular dystrophy, we hypothesized that restoration of skeletal muscle NPC1 levels could ameliorate the dystrophic phenotype. We tested this hypothesis by generating transgenic mice expressing *Npc1* specifically in skeletal muscle. We obtained four lines of transgenic NPC1 mice: Tg(*Npc1*)19, Tg(*Npc1*)55, Tg(*Npc1*)56, and Tg(*Npc1*)58. Two of these transgenic lines, Tg(*Npc1*)19 and Tg(*Npc1*)58, showed high expression of NPC1 in skeletal muscle (Figure 3). The transgenic mice showed no adverse effects of high levels on NPC1 in muscle. Expression of the NPC1 transgene results in a qualitative increase in the number of visible puncta but no increase in diffuse or sarcolemma labeling (Supplemental Figure 1). Each of the four Tg(*Npc1*) lines was crossed onto the *Dtna*^{-/-} and onto the *mdx* backgrounds.

Muscular dystrophy is characterized, in part, by increased numbers of regenerating muscle fibers (identified by central nucleation) and damaged muscle membranes. The latter leads to elevated levels of serum creatine kinase, which provides a body-wide assessment of myofiber sarcolemmal integrity. We assessed the effect of NPC1 expression on muscular dystrophy using these two parameters.

Transgenic NPC1 on *Dtna*^{-/-} Background

We determined the percentage of centrally-nucleated muscle fibers from H&E-stained cross sections of a predominantly slow-twitch (soleus), fast-twitch (TA), and respiratory (diaphragm) muscle of each genotype (Figure 4). In both the soleus and diaphragm muscles, transgenic expression of NPC1 restored central nuclei counts to wild-type levels. High expression of transgenic NPC1 significantly reduced the percentage of centrally nucleated myofibers by 83% [*Dtna*^{-/-}-Tg(NPC1)19] and 76% [*Dtna*^{-/-}-Tg(NPC1)58] relative to *Dtna*^{-/-}. We also observed smaller, but still statistically significant, reductions (40 and 34%) in the two lines expressing NPC1 at lower levels [*Dtna*^{-/-}-Tg(NPC1)55 and *Dtna*^{-/-}-Tg(NPC1)56, respectively] (data not shown). In diaphragm, central nuclei counts were significantly reduced in the two high NPC1-expressing transgenic lines [*Dtna*^{-/-}-

Figure 2. NPC1 localizes to lysosomes in skeletal muscle. (A) Immunofluorescence of individual muscle fibers from wild-type and *Npc1*^{-/-} quadriceps muscles. (B) Colabeling of the lysosome marker LAMP1 (red) with NPC1 (green) in wild-type muscle fibers. DAPI staining was used as a nuclei marker. Bar, 10 μ m.

Figure 3. Relative expression levels of *Npc1* in transgenic lines. Immunoblot analysis of NPC1 expression in diaphragm muscle homogenates from wild-type and four lines of *Dtna*^{-/-}-Tg(*Npc1*) mice. For comparison, 20 μ g of wild-type whole muscle homogenate was loaded versus 5 μ g for the *Dtna*^{-/-}-Tg(*Npc1*) mice. We estimate that transgenic expression levels of NPC1 are two- to fourfold (Tg55), four- to sixfold (Tg56), and 10- to 12-fold (Tg19 and Tg58) higher than wild-type levels. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was determined on the same blot as a loading control (bottom).

Tg(NPC1)19 (89%) and *Dtna*^{-/-}-Tg(NPC1)58 (93%)], but the two transgenic lines expressing NPC1 at low levels did not show significant decreases (data not shown). In the TA muscle, the percentage of myofibers with central nuclei was not significantly changed in all four transgenic lines compared with *Dtna*^{-/-} mice (Figure 4; data not shown).

Dtna^{-/-} transgenic mice expressing high levels of NPC1 also exhibited marked reductions in serum creatine kinase activity. As shown in Figure 4, transgenic expression of NPC1 in *Dtna*^{-/-} mice restored creatine kinase levels to wild-type levels in both the *Dtna*^{-/-}-Tg(NPC1)19 and *Dtna*^{-/-}-Tg(NPC1)58 lines. The reduced number of central nuclei and reduced serum creatine kinase levels demonstrate that the dystrophic phenotype in the *Dtna*^{-/-} mouse is ameliorated by transgenic skeletal muscle expression of NPC1. This amelioration is dose dependent and the degree of amelioration varies among the muscle fiber type.

Transgenic NPC1 on mdx Background

To determine whether high expression of NPC1 alters the phenotype in a model of severe muscular dystrophy, we used the *mdx* mouse, a mouse studied extensively as a model of DMD (Bulfield *et al.*, 1984). All four transgenic NPC1 lines were bred onto the *mdx* background (Figure 5). The extent of muscular dystrophy was assessed in 8-wk-old wild-type, *mdx*, and *mdx*-Tg(*Npc1*) mice by quantifying the percentage of centrally nucleated myofibers, determining serum creatine kinase activity and by measuring myofiber size variability (Figure 5).

In muscles of the soleus, TA, and diaphragm, high expression of NPC1 significantly reduced the percentage of centrally nucleated fibers relative to muscles from *mdx* mice (Figure 5). Transgenic expression of NPC1 in *mdx* mice also significantly reduced serum creatine kinase levels (Figure 5). Both of the transgenic lines expressing NPC1 at high levels [*mdx*-Tg(*Npc1*)19 and *mdx*-Tg(*Npc1*)58] showed sharply decreased creatine kinase levels (by 54 and 75%, respectively) compared with *mdx*. In fact, creatine kinase levels in *mdx*-Tg(*Npc1*)58 mice were not significantly different from wild-type levels.

An additional characteristic of dystrophic muscle is marked variability in muscle fiber diameter. We determined the variability of fiber diameter in the soleus muscle of the *mdx*-Tg(*Npc1*)58 mouse because it seemed to be the most

Figure 4. Amelioration of dystrophic phenotype in *Dtna*^{-/-} muscle by transgenic expression of *Npc1*. (A) H&E staining of soleus cross sections from wild-type, *Dtna*^{-/-}, and *Dtna*^{-/-}-Tg(*Npc1*)58 mice. Bar, 40 μ m. (B) Percentage of myofibers with central nuclei ($n \geq 5$ mice per genotype analyzed). (C) Serum creatine kinase levels. Data shown are mean $\pm$ SD; # $p < 0.05$ versus wild type; * $p < 0.05$ versus *Dtna*^{-/-}. Data were collected from mice 3 mo of age.

improved based on the degree of improvement in central nucleation and creatine kinase levels. Indeed, we found that although fiber sizes varied significantly in the *mdx* soleus compared with wild type, transgenic expression of NPC1 significantly reduced the size variability (Figures 5). Together, these data demonstrate that high expression of NPC1 in *mdx* skeletal muscle can significantly improve the dystrophic phenotype in this mouse model of Duchenne muscular dystrophy.

DISCUSSION

We used gene expression profiling of *Dtna*^{-/-} mouse muscle to identify downstream cellular and/or molecular alterations that result from the loss of α -dystrobrevin, and contribute to the onset of the muscular dystrophy of *Dtna*^{-/-} mice. *Dtna*^{-/-} muscle displays a milder dystrophic phenotype than *mdx* muscle (Grady *et al.*, 1999). Expression profiling studies of *mdx* muscle have yielded large changes associated with immune response and regeneration in the dystrophic muscle (Porter *et al.*, 2002; Porter *et al.*, 2004). To identify alterations in proteins and/or signaling pathways that lead to degeneration, we sought to minimize the influence of responses associated with inflammation and muscle repair by examining the less severely affected *Dtna*^{-/-} quadriceps

Figure 5. Transgenic expression of *Npc1* improves dystrophic phenotype of *mdx* mice. (A) H&E-stained cross sections of soleus muscles from wild-type, *mdx*, and *mdx*-Tg(*Npc1*)58 mice. Bar, 40 μ m. (B) Percentage of myofibers with central nuclei ($n \geq 5$ mice per genotype). (C) Serum creatine kinase levels. (D and E) Quantitative analyses of fiber diameter in soleus muscles of wild-type, *mdx*, and *mdx*-Tg(*Npc1*)58 mice, determined using Feret's diameter method. (D) Boxes represent the 25th to 75th percentiles, and lines represent high and low values. Data were pooled from ~500 fibers from each of three mice per genotype. (E) Coefficients of variation of soleus fiber diameters. Each data point represents the variance coefficient calculated from each mouse. Lines represent means (dark bar) $\pm$ SD (error bars). (A and C) Data shown are mean $\pm$ SD. (B, C, and E) # $p < 0.05$ versus wild type; * $p < 0.05$ versus *mdx*. Data obtained from 8-wk-old mice.

muscle at 6 wk of age. We analyzed large numbers of samples independently so statistical significance of small changes could be assessed. Selection of important changes was based on statistical significance, rather than an arbitrary magnitude change.

We identified >200 differentially expressed transcripts in the *Dtna*^{-/-} quadriceps muscle. Several of the genes with increased expression, such as insulin-like growth factor-II, are likely involved in muscle regeneration, similar to trends observed in publicly available data sets (Gene Expression Omnibus database; <http://www.ncbi.nlm.nih.gov/geo/>) from expression analyses of other dystrophy models (Bakay *et al.*, 2002; Haslett *et al.*, 2002; Porter *et al.*, 2002; Tseng *et al.*, 2002). In this study however, we focused on Niemann Pick type C1 (*Npc1*), which showed a highly significant ($p = 3.02 \times 10^{-7}$) ~50% decrease in transcript levels in *Dtna*^{-/-} mus-

cle. *Npc1* had previously not been associated with the muscular dystrophies. However, a search using Gene Expression Omnibus database revealed that *Npc1* transcript levels are decreased in muscles from *mdx* and dysferlin-null mice (Tseng *et al.*, 2002; Wenzel *et al.*, 2005).

NPC1 is a multispan membrane protein, residing primarily in late endosomes/lysosomes (Higgins *et al.*, 1999; Neufeld *et al.*, 1999; Garver *et al.*, 2000) as well as the trans-Golgi network (Higgins *et al.*, 1999) and caveolin-1 containing vesicles (Higgins *et al.*, 1999; Garver *et al.*, 2000). The absence of NPC1 results in intracellular accumulations of large amounts of unesterified cholesterol and glycosphingolipids in late endosomes/lysosomes. In skeletal muscle, we found that NPC1 is localized primarily in lysosomes. Although cholesterol has been shown to accumulate in every tissue of *Npc1*^{-/-} mice, including skeletal muscle (Xie *et al.*,

1999), the accumulation could not be observed in skeletal muscle fibers stained with filipin (Supplemental Figure 2). To our knowledge, neither the function of NPC1 in skeletal muscle, nor the effects of NPC1 deficiency in skeletal muscle has been examined.

To determine whether the reduction of NPC1 contributes to the muscular dystrophy of the *Dtna*^{-/-} mouse, we generated *Dtna*^{-/-} mice expressing transgenic *Npc1* under the control of the human skeletal α -actin (HSA) promoter (Brennan and Hardeman, 1993). Many of the dystrophic characteristics normally seen in *Dtna*^{-/-} muscle are ameliorated in *Dtna*^{-/-}-Tg(*Npc1*) mice. Serum creatine kinase levels and the percentage of centrally nucleated fibers in *Dtna*^{-/-} soleus and diaphragm muscles were restored to near normal levels by transgenic expression of NPC1. Perhaps more importantly, muscle-specific expression of NPC1 dramatically improved the phenotype of the more severely dystrophic *mdx* mice. Thus, our results suggest a new avenue for treatment of Duchenne muscular dystrophy in humans.

The loss or reduction of NPC1 by itself does not cause muscular dystrophy. We have examined several muscle types (TA, soleus, quadriceps, sternomastoid, and diaphragm) from 6-wk-old *Npc1*^{-/-}, as well as 6- and 16-wk-old *Npc*^{+/-} mice, and we have found no evidence of dystrophy in these mice (data not shown). However, we report here that transgenic expression of *Npc1* in *mdx* skeletal muscle ameliorates the dystrophic phenotype. Such an apparent paradox has also been observed in the case of neuronal nitric-oxide synthase (nNOS). Neither nNOS-null mice (Chao *et al.*, 1998), nor α -syntrophin-null mice (Kameya *et al.*, 1999; Adams *et al.*, 2000), which have reduced nNOS levels, are dystrophic. Yet, *mdx* mice, which also have reduced levels of nNOS (Brennan *et al.*, 1995), are dystrophic, and transgenic expression of nNOS ameliorates the dystrophy in *mdx* mice (Wehling *et al.*, 2001). A "two-hit" hypothesis has been suggested as a possible explanation for the discrepancy between the effect of nNOS reduction in the nNOS-null mouse and *mdx* mouse (Rando, 2001). According to this hypothesis, defects of the DPC are likely to have more than one biochemical consequence. Individually, either consequence may result in cell damage but alone is not enough to cause cell death; however, together they result in the severe necrosis observed in dystrophic muscle. In the case of nNOS, the reduction of nNOS causes ischemia in muscle as a result of the loss of protection to contraction-induced vasoconstriction ("first hit"), but DPC defects increase the vulnerability ("second hit") of the muscle to ischemia, causing injury to the muscle. Although the loss of NPC1 alone may not be sufficient to cause muscle fiber degeneration, it may in the presence of DPC defects contribute to the pathophysiology of dystrophic muscle.

The mechanism by which NPC1 dysfunction causes neuronal degeneration in Niemann-Pick disease is not fully understood. However, molecular abnormalities in NPC1-null cells suggest possible links to known causes of muscle degeneration. One particularly intriguing connection involves the caveolins. Caveolin-3, the muscle-specific form, binds directly to the dystrophin complex members, β -dystroglycan (Sotgia *et al.*, 2000) and nNOS (Garcia-Cardena *et al.*, 1997; Venema *et al.*, 1997) at the sarcolemma (Song *et al.*, 1996), and it is required for the correct targeting of the dystrophin complex to cholesterol-sphingolipid rafts/caveolae (Galbiati *et al.*, 2000).

A link between caveolin-3 regulation and the muscular dystrophies is well established. Muscles from Duchenne muscular dystrophy patients and *mdx* mouse muscles have elevated caveolin-3 levels (Vaghy *et al.*, 1998; Repetto *et al.*,

1999). Furthermore, mutations in caveolin-3 are the genetic basis for limb-girdle muscular dystrophy 1C (LGMD 1C) (Minetti *et al.*, 1998). Finally, a Duchenne-like muscular dystrophy results from transgenic overexpression of caveolin-3 in mouse muscle (Galbiati *et al.*, 2000).

Interestingly, elevated caveolin levels are also associated with NPC1 deficiency (Garver *et al.*, 1999; Garver *et al.*, 2002). In *Npc1*-heterozygous fibroblasts, caveolin levels are increased in plasma membrane caveolae (Garver *et al.*, 2002). Whether the link between caveolin and NPC1 has a role in ameliorating the dystrophic phenotype in skeletal muscle requires further study.

We have identified a significant reduction of NPC1, a cholesterol and sphingolipid trafficking protein, in α -dystrobrevin-null skeletal muscle. Furthermore, we show that transgenic expression of *Npc1* in skeletal muscle ameliorates the dystrophic phenotype of both *Dtna*^{-/-} and *mdx* mice, two models of muscular dystrophy. Because cholesterol is known to affect plasma membrane rigidity and lipid-protein interactions, and because caveolae are involved in intracellular signaling, alterations in the cholesterol content of sarcolemmas or caveolae could adversely affect the structural integrity of the sarcolemmas, the ability of the membranes to repair themselves (Hernández-Deviez *et al.*, 2008), and/or the localization/function of caveolar signaling proteins. The involvement of NPC1 offers new therapeutic targets for muscular dystrophies resulting from abnormalities of the dystrophin complex.

ACKNOWLEDGMENTS

We thank Josh Sanes and Mark Grady for providing the *Dtna*^{-/-} mice and Jeff Chamberlain for the HSA expression vector. This research was supported by National Institutes of Health grants P01 NS046788 and R01 NS33145 (to S.C.F.).

REFERENCES

- Adams, M. E., Kramarcy, N., Krall, S. P., Rossi, S. G., Rotundo, R. L., Sealock, R., and Froehner, S. C. (2000). Absence of alpha-syntrophin leads to structurally aberrant neuromuscular synapses deficient in utrophin. *J. Cell Biol.* 150, 1385–1398.
- Bakay, M., Zhao, P., Chen, J., and Hoffman, E. P. (2002). A web-accessible complete transcriptome of normal human and DMD muscle. *Neuromuscul. Disord.* 12 (suppl 1), S125–S141.
- Brennan, J. E., Chao, D. S., Xia, H., Aldape, K., and Bredt, D. S. (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell* 82, 743–752.
- Brennan, K. J., and Hardeman, E. C. (1993). Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice. *J. Biol. Chem.* 268, 719–725.
- Briguet, A., Courdier-Fruh, I., Foster, M., Meier, T., and Magyar, J. P. (2004). Histological parameters for the quantitative assessment of muscular dystrophy in the *mdx*-mouse. *Neuromuscul. Disord.* 14, 675–682.
- Bulfield, G., Siller, W. G., Wight, P. A., and Moore, K. J. (1984). X chromosome-linked muscular dystrophy (*mdx*) in the mouse. *Proc. Natl. Acad. Sci. USA* 81, 1189–1192.
- Carozzi, A. J., Ikonen, E., Lindsay, M. R., and Parton, R. G. (2000). Role of cholesterol in developing T-tubules: analogous mechanisms for T-tubule and caveolae biogenesis. *Traffic* 1, 326–341.
- Chao, D. S., Silvagno, F., and Bredt, D. S. (1998). Muscular dystrophy in *mdx* mice despite lack of neuronal nitric oxide synthase. *J. Neurochem.* 71, 784–789.
- Cox, G. A., Cole, N. M., Matsumura, K., Phelps, S. F., Hauschka, S. D., Campbell, K. P., Faulkner, J. A., and Chamberlain, J. S. (1993). Overexpression of dystrophin in transgenic *mdx* mice eliminates dystrophic symptoms without toxicity. *Nature* 364, 725–729.
- Crawford, G. E., Faulkner, J. A., Crosbie, R. H., Campbell, K. P., Froehner, S. C., and Chamberlain, J. S. (2000). Assembly of the dystrophin-associated

- protein complex does not require the dystrophin COOH-terminal domain. *J. Cell Biol.* 150, 1399–1410.
- Engvall, E., and Wewer, U. M. (2003). The new frontier in muscular dystrophy research: booster genes. *FASEB J.* 17, 1579–2584.
- Ervasti, J. M. (2007). Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. *Biochim. Biophys. Acta* 1772, 108–117.
- Ervasti, J. M., Ohlendieck, K., Kahl, S. D., Gaver, M. G., and Campbell, K. P. (1990). Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. *Nature* 345, 315–319.
- Galbiati, F. *et al.* (2000). Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. *Proc. Natl. Acad. Sci. USA* 97, 9689–9694.
- Garcia-Cardena, G., Martasek, P., Masters, B. S., Skidd, P. M., Couet, J., Li, S., Lisanti, M. P., and Sessa, W. C. (1997). Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. *J. Biol. Chem.* 272, 25437–25440.
- Garver, W. S., Heidenreich, R. A., Erickson, R. P., Thomas, M. A., and Wilson, J. M. (2000). Localization of the murine Niemann-Pick C1 protein to two distinct intracellular compartments. *J. Lipid Res.* 41, 673–687.
- Garver, W. S., Hossain, G. S., Winscott, M. M., and Heidenreich, R. A. (1999). The Npc1 mutation causes an altered expression of caveolin-1, annexin II and protein kinases and phosphorylation of caveolin-1 and annexin II in murine livers. *Biochim. Biophys. Acta* 1453, 193–206.
- Garver, W. S., Krishnan, K., Gallagos, J. R., Michikawa, M., Francis, G. A., and Heidenreich, R. A. (2002). Niemann-Pick C1 protein regulates cholesterol transport to the trans-Golgi network and plasma membrane caveolae. *J. Lipid Res.* 43, 579–589.
- Grady, R. M., Grange, R. W., Lau, K. S., Maimone, M. M., Nichol, M. C., Stull, J. T., and Sanes, J. R. (1999). Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. *Nat. Cell Biol.* 1, 215–220.
- Gregorevic, P. *et al.* (2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. *Nat. Med.* 12, 787–789.
- Haslett, J. N., Sanoudou, D., Kho, A. T., Bennett, R. R., Greenberg, S. A., Kohane, I. S., Beggs, A. H., and Kunkel, L. M. (2002). Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. *Proc. Natl. Acad. Sci. USA* 99, 15000–15005.
- Hernández-Deviez, D. J., Howes, M. T., Laval, S. H., Bushby, K., Hancock, J. F., and Parton, R. G. (2008). Caveolin regulates endocytosis of the muscle repair protein, dysferlin. *J. Biol. Chem.* 283, 6476–6488.
- Higgins, M. E., Davies, J. P., Chen, F. W., and Ioannou, Y. A. (1999). Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network. *Mol. Genet. Metab.* 68, 1–13.
- Hoffman, E. P., Brown, R. H., and Kunkel, L. M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* 51, 919–928.
- Kameya, S., Miyagoe, Y., Nonaka, I., Ikemoto, T., Endo, M., Hanaoka, K., Nabeshima, Y., and Takeda, S. (1999). alpha-Syntrophin gene disruption results in the absence of neuronal-type nitric oxide synthase at the sarcolemma but does not induce muscle degeneration. *J. Biol. Chem.* 274, 2193–2200.
- Liscum, L., Ruggiero, R. M., and Faust, J. R. (1989). The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. *J. Cell Biol.* 108, 1625–1636.
- Minetti, C. *et al.* (1998). Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. *Nat. Genet.* 18, 365–368.
- Neufeld, E. B. *et al.* (1999). The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. *J. Biol. Chem.* 274, 9627–9635.
- Ozawa, E., Mizuno, Y., Hagiwara, Y., Sasaoka, T., and Yoshida, M. (2005). Molecular and cell biology of the sarcoglycan complex. *Muscle Nerve* 32, 563–576.
- Percival, J. M., Gregorevic, P., Odom, G. L., Banks, G. B., Chamberlain, J. S., and Froehner, S. C. (2007). rAAV6-microdystrophin rescues aberrant Golgi complex organization in mdx skeletal muscles. *Traffic* 8, 1424–1439.
- Porter, J. D. *et al.* (2002). A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. *Hum. Mol. Genet.* 11, 263–272.
- Porter, J. D., Merriam, A. P., Leahy, P., Gong, B., Feuerman, J., Cheng, G., and Khanna, S. (2004). Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. *Hum. Mol. Genet.* 13, 257–269.
- Ragot, T. *et al.* (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. *Nature* 361, 647–650.
- Rando, T. A. (2001). Role of nitric oxide in the pathogenesis of muscular dystrophies: a “two hit” hypothesis of the cause of muscle necrosis. *Microsc. Res. Tech.* 55, 223–235.
- Repetto, S. *et al.* (1999). Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. *Biochem. Biophys. Res. Commun.* 261, 547–550.
- Sokol, J. *et al.* (1988). Type C Niemann-Pick disease. Lysosomal accumulation and defective intracellular mobilization of low density lipoprotein cholesterol. *J. Biol. Chem.* 263, 3411–3417.
- Song, K. S., Scherer, P. E., Tang, Z., Okamoto, T., Li, S., Chafel, M., Chu, C., Kohtz, D. S., and Lisanti, M. P. (1996). Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. *J. Biol. Chem.* 271, 15160–15165.
- Sotgia, F. *et al.* (2000). Caveolin-3 directly interacts with the C-terminal tail of β -dystroglycan. Identification of a central WW-like domain within caveolin family members. *J. Biol. Chem.* 275, 38048–38058.
- Tseng, B. S., Zhao, P., Pattison, J. S., Gordon, S. E., Granchelli, J. A., Madsen, R. W., Folk, L. C., Hoffman, E. P., and Booth, F. W. (2002). Regenerated mdx mouse skeletal muscle shows differential mRNA expression. *J. Appl. Physiol.* 93, 537–545.
- Vaghy, P. L., Fang, J., Wu, W., and Vaghy, L. P. (1998). Increased caveolin-3 levels in mdx mouse muscles. *FEBS Lett.* 431, 125–127.
- Venema, V. J., Ju, H., Zou, R., and Venema, R. C. (1997). Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. *J. Biol. Chem.* 272, 28187–28190.
- Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. *Proc. Natl. Acad. Sci. USA* 97, 13714–13719.
- Wehling, M., Spencer, M. J., and Tidball, J. G. (2001). A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. *J. Cell Biol.* 155, 123–131.
- Wenzel, K. *et al.* (2005). Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. *J. Immunol.* 175, 6219–6225.
- Xie, C., Turley, S. D., Pentchev, P. G., and Dietschy, J. M. (1999). Cholesterol balance and metabolism in mice with loss of function of Niemann-Pick C protein. *Am. J. Physiol.* 276, E336–E344.